Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01202890
Recruitment Status : Terminated (Terminated due to inadequate rate of accrual.)
First Posted : September 16, 2010
Last Update Posted : January 8, 2014
Celgene Corporation
Information provided by (Responsible Party):
New Mexico Cancer Care Alliance

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Primary Completion Date : May 2011
  Study Completion Date : May 2012